摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[4-(aminosulfonyl)phenyl]-1-(2'-acetamido-2'-deoxy-β-D-glucopyranosyl)-1H-1,2,3-triazole | 1017276-64-0

中文名称
——
中文别名
——
英文名称
4-[4-(aminosulfonyl)phenyl]-1-(2'-acetamido-2'-deoxy-β-D-glucopyranosyl)-1H-1,2,3-triazole
英文别名
N-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[4-(4-sulfamoylphenyl)triazol-1-yl]oxan-3-yl]acetamide
4-[4-(aminosulfonyl)phenyl]-1-(2'-acetamido-2'-deoxy-β-D-glucopyranosyl)-1H-1,2,3-triazole化学式
CAS
1017276-64-0
化学式
C16H21N5O7S
mdl
——
分子量
427.438
InChiKey
WRBIMYXSAKHNPY-OXGONZEZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.3
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    198
  • 氢给体数:
    5
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    4-[4-(aminosulfonyl)phenyl]-1-(2'-acetamido-2'-deoxy-3',4',6'-tri-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazolesodium methylate 作用下, 以 甲醇 为溶剂, 反应 0.5h, 以116 mg的产率得到4-[4-(aminosulfonyl)phenyl]-1-(2'-acetamido-2'-deoxy-β-D-glucopyranosyl)-1H-1,2,3-triazole
    参考文献:
    名称:
    Inhibition of Carbonic Anhydrases with Glycosyltriazole Benzene Sulfonamides
    摘要:
    library of glycoconjugate benzene sulfonamides have been synthesized and investigated for their ability to inhibit the enzymatic activity of physiologically relevant human carbonic anhydrase (hCA) isozymes: hCA I, II, and tumor-associated IX. Our synthetic strategy directly links the known CA pharmacophore (ArSO2NH2) to a sugar "tail" moiety through a rigid 1,2,3-triazole linker unit using the Cu(I)-catalyzed 1,3-dipolar cycloaddition reaction or "click chemistry". Many of the glycoconjugates were potent CA inhibitors and exhibited some isozyme selectivity. In particular, the methyl-D-glucuronate triazoles 6 and 14 were potent inhibitors of hCA IX (K(i)s 9.9 and 8.4 nM, respectively) with selectivity also favoring this isozyme. Other exceptional compounds included the deprotected beta-D-ribofuranosyl triazole 15 and alpha-D-mannosyl triazole 17, which were potent and selective hCA II inhibitors (K-i 7.5 nM and K-i 2.3 nM, respectively). Collectively, the results confirm that modification of ring size, stereochemical configuration, and chain length in the sugar tail moiety of glycoconjugate CA inhibitors permits tunable potency and selectivity that may constitute an important avenue for the future development of efficacious and selective CA-based therapeutics.
    DOI:
    10.1021/jm701426t
点击查看最新优质反应信息

文献信息

  • Inhibition of Carbonic Anhydrases with Glycosyltriazole Benzene Sulfonamides
    作者:Brendan L. Wilkinson、Alessio Innocenti、Daniela Vullo、Claudiu T. Supuran、Sally-Ann Poulsen
    DOI:10.1021/jm701426t
    日期:2008.3.1
    library of glycoconjugate benzene sulfonamides have been synthesized and investigated for their ability to inhibit the enzymatic activity of physiologically relevant human carbonic anhydrase (hCA) isozymes: hCA I, II, and tumor-associated IX. Our synthetic strategy directly links the known CA pharmacophore (ArSO2NH2) to a sugar "tail" moiety through a rigid 1,2,3-triazole linker unit using the Cu(I)-catalyzed 1,3-dipolar cycloaddition reaction or "click chemistry". Many of the glycoconjugates were potent CA inhibitors and exhibited some isozyme selectivity. In particular, the methyl-D-glucuronate triazoles 6 and 14 were potent inhibitors of hCA IX (K(i)s 9.9 and 8.4 nM, respectively) with selectivity also favoring this isozyme. Other exceptional compounds included the deprotected beta-D-ribofuranosyl triazole 15 and alpha-D-mannosyl triazole 17, which were potent and selective hCA II inhibitors (K-i 7.5 nM and K-i 2.3 nM, respectively). Collectively, the results confirm that modification of ring size, stereochemical configuration, and chain length in the sugar tail moiety of glycoconjugate CA inhibitors permits tunable potency and selectivity that may constitute an important avenue for the future development of efficacious and selective CA-based therapeutics.
查看更多